Table 2. 32 noticeable occurrence frequency breakpoint regions (NOF-BPRs), which was found in at least 10% of all samples in the single tumor entities and/or the healthy tissues.

chr	SNP A	SNP B	breast	color.	gastr.	lung	medul.	ov.	pro.	renal	normal	class
2	172,338,300	172,339,964	7.96	14.29	0.29	1.72	2.26	8.21	0.00	7.34	0.69	3
	172,345,151	172,348,021	4.51	14.29	0.00	1.37	1.63	7.73	0.00	7.34	0.69	3
4	3,027,493	3,027,897	0.00	0.00	11.47	0.00	0.00	0.00	0.00	1.83	1.39	3
	3,029,623	3,035,631	0.00	0.00	11.76	0.00	0.00	0.00	0.00	1.83	1.16	3
	9,994,215	9,996,852	12.47	0.00	1.47	1.37	0.00	0.00	0.00	3.67	0.00	2
	9,997,801	10,001,833	13.79	0.00	7.35	3.44	0.00	0.00	0.00	3.67	0.00	2
5	4,430,296	4,431,868	0.27	0.00	11.18	0.69	0.00	0.00	0.00	0.00	1.16	1
	4,443,854	4,445,976	0.27	0.00	18.53	2.06	0.00	0.00	0.00	0.00	0.93	3
	61,569,169	61,572,989	0.00	0.00	0.00	0.34	1.09	0.00	0.00	12.84	0.46	2
	126,152,745	126,158,200	0.27	0.00	0.00	1.37	1.54	0.00	0.00	10.09	1.16	3
6	67,048,629	67,049,406	2.39	12.70	2.65	2.75	1.18	0.48	0.00	4.59	0.46	2
	77,422,497	77,439,868	7.16	10.05	2.35	5.15	6.07	4.83	1.67	5.50	3.24	3
7	35,396,655	35,397,567	0.00	0.00	1.03	3.82	0.27	11.59	5.83	0.00	8.33	3
8	6,104,977	6,107,427	1.59	15.87	1.18	1.03	1.36	5.31	0.00	8.26	0.23	2
	39,225,941	39,288,762	7.69	12.17	4.71	8.25	8.79	4.35	0.83	9.17	5.56	3
	39,397,732	39,398,022	7.43	11.11	4.71	8.25	8.79	4.83	0.83	9.17	5.09	3
	43,778,914	46,924,211	9.02	3.70	2.65	7.22	0.63	8.21	14.17	5.50	3.01	3
9	9,337,599	9,338,146	0.27	0.53	13.53	0.34	0.00	0.00	0.00	0.00	0.46	1
	9,338,417	9,339,871	0.27	0.53	11.76	0.69	0.00	0.00	0.00	0.00	0.46	1
10	44,051,819	44,065,519	0.53	0.00	0.00	1.03	0.36	0.00	0.00	10.09	0.23	2
11	9,241,448	9,250,359	1.06	1.06	0.29	1.72	2.90	0.97	0.00	11.01	0.93	3
14	35,070,371	35,076,347	0.00	0.00	0.00	0.34	0.45	0.00	0.00	10.09	0.46	1
16	70,842,097	70,854,381	15.38	0.00	0.29	1.03	1.81	0.48	0.00	0.00	0.23	2
	85,082,710	85,091,864	0.27	4.76	0.29	0.34	15.58	1.45	0.00	10.09	0.23	2
	85,091,864	85,092,483	11.14	22.75	9.41	26.12	27.90	21.26	0.00	11.01	4.86	3
	85,092,748	85,092,892	9.81	27.51	9.71	25.43	43.48	22.71	0.00	21.10	5.09	3
17	18,917,513	18,917,915	1.86	1.59	0.29	0.69	10.05	0.00	0.00	0.00	0.00	2
	18,917,915	19,168,912	0.53	0.53	0.00	0.00	15.40	0.00	0.00	0.00	0.00	1
18	4,976,160	4,979,612	0.27	16.40	4.12	0.00	1.36	0.00	0.00	25.69	11.81	3
	4,989,683	4,990,804	0.27	11.64	2.35	0.00	2.08	0.00	2.50	20.18	11.34	3
21	23,655,764	23,655,900	0.00	0.53	10.00	12.03	0.63	5.31	3.33	0.00	6.71	3
	23,664,658	23,667,121	0.53	2.65	11.47	13.40	3.62	11.59	7.50	0.92	9.03	3

BPRs are provided with their related chromosome (chr), start (SNP A) and end (SNP B) positions, absolute occurrence probability in the tumor entities (breast, color., gastr., lung, medul., ov., pro., renal), and the total occurrence over all tumor samples (cancer) and in healthy tissue samples (normal), respectively, and the related classification of the BPRs (tumor entity-specific (1)—occurrence is ≥ 1% in exclusively one tumor entity with or without being found in healthy samples, cancer-specific (2)—occurrence is ≥ 1% in more than 25% of the entities and in normal samples < 0.5%, common (3)—occurrence is ≥ 1% in ≥ 25% of the entities and ≥ 0.5% in normal samples.

Abbreviations: color.—colorectal; gastr.—gastric; medul.—pediatric medulloblastoma; ov.—ovarian; pro.—prostate; ren.—renal